Moreover, the 36-month beta value for PHIO is 1.38. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PHIO is 4.52M and currently, short sellers hold a 0.47% of that float. On April 23, 2024, PHIO’s average trading volume was 317.62K shares.
PHIO) stock’s latest price update
The stock of Phio Pharmaceuticals Corp (NASDAQ: PHIO) has increased by 29.69 when compared to last closing price of 0.64. Despite this, the company has experienced a 24.68% gain in its stock price over the last five trading sessions. PennyStocks reported 2023-12-05 that Penny stocks, defined as those trading under $5 per share, offer unique opportunities. With low prices and the potential for high percentage returns, it’s understandable why penny stocks attract interest from new traders.
PHIO’s Market Performance
Phio Pharmaceuticals Corp (PHIO) has experienced a 24.68% rise in stock performance for the past week, with a -1.20% drop in the past month, and a 23.88% rise in the past quarter. The volatility ratio for the week is 18.17%, and the volatility levels for the past 30 days are at 10.37% for PHIO. The simple moving average for the last 20 days is 21.06% for PHIO stock, with a simple moving average of -38.08% for the last 200 days.
Analysts’ Opinion of PHIO
Many brokerage firms have already submitted their reports for PHIO stocks, with H.C. Wainwright repeating the rating for PHIO by listing it as a “Buy.” The predicted price for PHIO in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on August 05, 2020 of the previous year 2020.
PHIO Trading at 4.81% from the 50-Day Moving Average
After a stumble in the market that brought PHIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.88% of loss for the given period.
Volatility was left at 10.37%, however, over the last 30 days, the volatility rate increased by 18.17%, as shares surge +14.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.54% upper at present.
During the last 5 trading sessions, PHIO rose by +24.68%, which changed the moving average for the period of 200-days by -72.34% in comparison to the 20-day moving average, which settled at $0.6908. In addition, Phio Pharmaceuticals Corp saw 9.20% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHIO starting from Bitterman Robert J, who purchase 2,500 shares at the price of $0.91 back on Feb 26 ’24. After this action, Bitterman Robert J now owns 18,990 shares of Phio Pharmaceuticals Corp, valued at $2,275 using the latest closing price.
Bitterman Robert J, the President & CEO of Phio Pharmaceuticals Corp, purchase 1,000 shares at $2.84 during a trade that took place back on Jul 01 ’23, which means that Bitterman Robert J is holding 19,211 shares at $2,840 based on the most recent closing price.
Stock Fundamentals for PHIO
The total capital return value is set at -1.38. Equity return is now at value -116.60, with -97.63 for asset returns.
Based on Phio Pharmaceuticals Corp (PHIO), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -307.11.
Currently, EBITDA for the company is -10.51 million with net debt to EBITDA at 0.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.71.
Conclusion
To wrap up, the performance of Phio Pharmaceuticals Corp (PHIO) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
